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ABSTRACT
Potential risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii were investigated
in a cohort study in 25 Spanish hospitals. The clonal relationship among isolates was determined by
pulsed-field gel electrophoresis (PFGE). In total, A. baumannii was isolated from 203 patients, with
imipenem-resistant (MIC90 128 mg ⁄L) isolates being obtained from 88 patients (43%), and imipenem-
susceptible isolates from 115 patients (57%). A wide clonal distribution was observed among the
imipenem-resistant isolates, but spread of the same clone among centres was not demonstrated. The
results indicated that imipenem-resistant A. baumannii is a widely distributed nosocomial pathogen in
Spain and reaches an alarming frequency in some centres. Independent risk-factors for the acquisition of
imipenem-resistant A. baumannii were a hospital size of > 500 beds (multivariate OR, 6.5; 95% CI,
1.8–23), previous antimicrobial treatment (multivariate OR, 4.3; 95% CI, 1.6–11), a urinary catheter
(multivariate OR, 2.7; 95% CI, 1.1–6.7) and surgery (multivariate OR, 2; 95% CI, 1.07–3.8).
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INTRODUCTION
Acinetobacter baumannii is an important nosoco-
mial pathogen in developed countries which is
difficult to both control and treat because of its
prolonged environmental survival and its ability
to develop resistance to multiple antimicrobial
agents [1,2]. In general, imipenem is the agent
most active against A. baumannii. In a study in 49
USA hospitals, in which 111 episodes of bacter-
aemia caused by A. baumannii were analysed,
imipenem was active in vitro against all the
isolates (MIC90 1 mg ⁄L) [3]. However, reports of
imipenem-resistant A. baumannii (IMP-R A. bau-
mannii) strains have been rising steadily during
the past few years, and these isolates are often
multidrug-resistant [4–8]. It is likely that mul-
tiple mechanisms account for carbapenem resist-
ance in A. baumannii [9,10]. These data are
disturbing because inappropriate empirical anti-
microbial treatment increases mortality in
patients with bacteraemia [11,12].
Previous studies of risk-factors for the acquisi-
tion of IMP-R A. baumannii have focused on a
single city or institution [4,6,7]. These studies
have suggested that previous use of third-gen-
eration cephalosporins or carbapenems, admis-
sion to a ward with a high density of patients
infected with IMP-R A. baumannii, and a high
workload all contribute to acquisition of carbape-
nem-resistant A. baumannii [4,6,7]. Recently, a
case-control study suggested that the risk-factors
for nosocomial IMP-R A. baumannii infection were
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previous stay in an intensive care unit (ICU), and
previous exposure to imipenem or third-genera-
tion cephalosporins [13]. However, more data
regarding the risk-factors for IMP-R A. baumannii
colonisation ⁄ infection are needed in order to
prevent infection and to optimise therapy.
The present study investigated the risk-factors
for the acquisition of IMP-R A. baumannii as part
of a nationwide study in Spain. Genotypic analy-
sis using pulsed-field gel electrophoresis (PFGE)
was used to determine whether inter-hospital
spread of imipenem-resistant isolates had
occurred.
METHODS
Participating hospitals
Members of the Spanish Group for Nosocomial Infection
(GEIH) from the Spanish Society of Infectious Diseases and
Clinical Microbiology (SEIMC) were asked to participate in the
GEIH-Ab 2000 project, which was designed to investigate the
epidemiology, mechanisms of resistance and clinical implica-
tions of A. baumannii in Spanish hospitals. The 28 participating
hospitals serve a population of 11 million (c. 25% of the total
population of Spain). Twenty-six (92.8%) of the participants
were public hospitals, 14 (50%) were university hospitals, and
19 (67.8%) had active transplant programmes. Eleven (39.3%)
had > 1000 beds, ten (35.7%) had 500–999 beds, and seven
(25%) had < 500 beds.
Study definitions
Every new case of colonisation or infection caused by A.
baumannii during November 2000 in the participating hos-
pitals was included. For each case, only the first isolate was
included.
The breakpoint for defining imipenem-susceptible A. bau-
mannii (IMP-S A. baumannii) was an MIC £ 4 mg ⁄L, and a
breakpoint of ‡ 8 mg ⁄L was used for IMP-R A. baumannii, i.e.,
intermediate and resistant isolates [14,15]. A. baumannii was
considered to be acquired nosocomially if the specimen was
obtained > 2 days after the admission of the patient to hospital.
The clinical significance (colonisation or infection) of each A.
baumannii isolate and the type of infection were assessed
according to CDC criteria [16,17].
Risk-factor analysis
The following data were collected: age, gender, presence or
absence of underlying conditions, hospital size (i.e., > 500
or < 500 beds), type of hospital ward (ICU, medical, surgical
or paediatric), treatment with antimicrobial agents, number
and classes of antimicrobial agent, intravenous, arterial or
urinary catheter, nasogastric tube, parenteral nutrition,
mechanical ventilation, surgical procedures, and ICU and
hospital stay before infection ⁄ colonisation. Patients were
followed until discharge or death, or until 30 days after
the specimen had been obtained if the patient was still
hospitalised.
Microbiological studies
All isolates identified presumptively as A. baumannii in each
participating hospital were sent to a reference laboratory
(Hospital Clinic, Barcelona), where identification was per-
formed initially with the API 20 NE system (bioMe´rieux,
Marcy l’Etoile, France) and confirmed by amplified ribosomal
DNA restriction analysis [18].
PFGE was used to determine whether inter-hospital spread
of imipenem-resistant isolates had occurred, following the
methodology described by Gautom [19], with 20 U of ApaI
used for restriction endonuclease digestion. DNA fragments
were separated in an agarose 1% w ⁄v gel and electrophoresed
in 0.5· Tris-borate-EDTA buffer at 6 V ⁄ cm on a contour-
clamped homogeneous electric field apparatus (CHEF DRIII;
Bio-Rad Laboratories, Richmond, CA, USA). Pulse times were
from 5 to 8 s for 20 h. The gels were stained with ethidium
bromide and photographed under UV light. Isolates were
assigned to clonal groups according to the criteria of Tenover
et al. [20].
Antimicrobial susceptibility to imipenem (Merck Sharp &
Dohme, Madrid, Spain) was determined by microdilution
following NCCLS recommendations [15].
Statistical analysis
Data were recorded on standardised forms and entered into
a database. Analyses were performed using SPSS software,
v. 11.0 (SPSS Inc., Chicago, IL, USA). Categorical variables
were compared by Fisher’s exact test. If continuous data
were distributed normally, the ANOVA test was used; other-
wise, non-parametric two-sample tests were used. Variables
with a p value < 0.1 in the univariate analysis were included
in the multivariate analysis. Multivariate stepwise (forward)
logistic regression analysis was performed to determine
independent risk-factors for acquiring imipenem resistance.
The optimal variables, on the basis of clinical significance,
were included in the final model. Co-linearity was discarded.
All statistical analyses were two-sided, and significance was
set at p < 0.05.
RESULTS
Clinical and microbiological findings
During the study period, 240 isolates identified
presumptively as A. baumannii were sent to the
reference laboratory. Nineteen isolates were
excluded: one was not Acinetobacter spp.; 15 were
identified as Acinetobacter genospecies 3 [21]; and
three were Acinetobacter spp. other than A. bau-
mannii. Thus, in total, 25 (89.2%) of the 28
participating hospitals had 221 patients with
A. baumannii colonisation or infection during the
study period. The clinical features and epidemi-
ology of these patients, as well as the clonal
diversity, antimicrobial susceptibility and type-1
integron content of the isolates, have been des-
cribed previously [22–24]. The present study of
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risk-factors included 203 patients with A. bau-
mannii colonisation or infection; 18 (8%) patients
were excluded because of incomplete clinical
records.
The MIC50 and the MIC90 of imipenem for the
isolates were 1 and 128 mg ⁄L, respectively.
Eighty-eight isolates (43.3%) were imipenem-
resistant (including 13 (6.4%) with intermediate
susceptibility) and 115 (56.6%) were imipenem-
susceptible. The IMP-R A. baumannii isolates were
more resistant to other antimicrobial agents than
were the IMP-S isolates [23]. IMP-R isolates were
detected in 11 (39.3%) hospitals, and IMP-S
isolates in 22 (79%) hospitals. The geographical
distribution of the hospitals is shown in Fig. 1.
PFGE identified 27 different clones among the
IMP-R isolates (Table 1). No single clone was
detected in more than one hospital, but 21 isolates
of the same IMP-R clone (PFGE type 72) were
isolated from different patients in a single hospi-
tal (no. 21), confirming intra-institutional spread.
The pooled mean incidence of IMP-R A. bau-
mannii colonisation or infection was 1.36 cases per
1000 admissions, with a range according to centre
of 0–34 (Table 1). Patients were either colonised
(51%) or infected (49%) with IMP-R A. baumannii.
The types of infections and mortality rates were
similar for patients with IMP-R and IMP-S
A. baumannii (Table 2). The overall mortality rate
was 19% (39 of 203). The mortality rate of patients
with infection (29 of 108; 27%) was higher than
that of patients with A. baumannii colonisation
(10 of 95; 11%; p < 0.01).
Risk-factors
The results of the univariate analysis revealed
significant differences between the patients with
IMP-R or IMP-S A. baumannii in terms of hospital
size, previous ICU stay, ICU ward, previous
antimicrobial treatment, number of antimicrobial
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participating hospitals.
Table 1. Incidence, distribution and PFGE types of imipe-
nem-resistant Acinetobacter baumannii isolated from 25
hospitals
Hospital
Ab
n
IMP-R
Ab n
PFGE types
(no. of isolates)
Incidence of
IMP-R Ab
(cases/1000
admissions)
1 2 0 – 0
2 3 0 – 0
3 12 2 41 (2) 1.2
4 7 0 – 0
5 4 4 44 (4) 0.9
6 12 5 47 (3), 48 (2) 1.5
7 8 0 – 0
8 7 6 50 (5), 52 (1) 3.0
9 12 7 53 (6), 54 (1) 1.5
10 1 0 – 0
11 1 0 – 0
12 1 0 – 0
13 1 0 – 0
14 7 0 – 0
15 8 0 – 0
16 1 1 11 (1) 0.3
17 3 0 – 0
18a 22 3 15 (1), 22 (2) 34.0
19 2 1 32 (1) 0.3
20 3 3 34 (2), 35 (1) 1.5
21 37 31 71 (4), 72 (21), 73 (2), 74, 75, 78 and 79 (1) 12.4
22 42 25 56 (12), 57 (3), 59 (2), 61 (6), 65 and 67 (1) 5.6
23 5 0 – 0
24 1 0 – 0
25 1 0 - 0
Total 203 88 27 types 1.36
aChronic-care centre.
Ab, Acinetobacter baumannii; IMP-R Ab, imipenem-resistant A. baumannii; PFGE,
pulsed-field gel electrophoresis.
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agents prescribed, treatment with carbapenems,
cephalosporins or aminoglycosides, intravenous
catheters, intra-arterial catheters, urinary cathe-
ters, nasogastric tubes, mechanical ventilation and
surgical treatment (Table 3). The larger hospitals
participating in the study were mainly university
hospitals, with transplant units, haematology–
oncology services and large ICUs. The smaller
hospitals were in rural locations and provided
general medicine, surgery and paediatric services.
Logistic regression analysis indicated that a hos-
pital with > 500 beds (OR, 6.61; 95% CI, 1.8–23.2),
antimicrobial treatment (OR, 4.36; 95% CI, 1.6–
11.5), a urinary catheter (OR, 2.77; 95% CI,
1.1–6.8) and previous surgery (OR, 2.02; 95% CI,
1.07–3.8) were independent risk-factors for the
acquisition of IMP-R A. baumannii.
DISCUSSION
The study confirmed that IMP-R A. baumannii is
an important nosocomial pathogen that is distri-
buted widely throughout Spain. IMP-R A. bau-
mannii was isolated in 39% of the participating
hospitals. The distribution did not follow a
geographical pattern; thus, some hospitals in a
city had a high incidence of this pathogen, while
other hospitals in the same city did not (Fig. 1).
These differences probably reflect different pat-
terns of antimicrobial use, epidemiological cir-
cumstances and the infection control programmes
in each centre, as has been described for hospitals
in Brooklyn, USA [4].
The overall incidence of IMP-R A. baumannii
infection ⁄ colonisation in Spain is quite high, i.e.,
1.36 cases ⁄ 1000 hospital admissions, and is also
highly variable between centres (0–34 cases ⁄ 1000
hospital admissions). Although there are no sim-
ilar published studies with which to compare the
incidence of patients with IMP-R A. baumannii,
various studies have reported that the incidence
of imipenem resistance in Acinetobacter spp. is
6–8% in the USA and Canada, 10% in Latin
America, and 16% in Europe [25–27]. The overall
frequency of IMP-R A. baumannii in the present
study was 43%, suggesting that there is room for
improvement in the prevention and control meas-
ures for IMP-R A. baumannii infections in Spain.
The study showed that IMP-R A. baumannii has
great clonal variability in Spain, and that poly-
clonal dissemination predominates. Thus, there
were 27 different clones among the 88 IMP-R
A. baumannii isolates. Endemic polyclonal dissem-
ination of IMP-R A. baumannii was demonstrated
in seven (64%) of 11 participating centres, while
epidemic monoclonal dissemination was shown
in four (36%) centres (Table 1). The genetic
heterogeneity of IMP-R A. baumannii in Spain
has been found previously at a local level in
single-centre studies [6,28], but a nationwide
study has not been performed previously. The
present study did not detect inter-hospital dis-
semination of a single IMP-R A. baumannii clone,
and nor did it detect dissemination between
hospitals in a single city. These findings are in
contrast with those from Brooklyn, USA, where
85% of the 275 isolates corresponded to two
Table 2. Acinetobacter baumannii infections (n = 108) and
mortality rate
Type of infection
Patients with
IMP-R Ab n (%)
Patients with
IMP-S Ab n (%) p
Pneumonia 15 (35) 21 (32) NS
Tracheobronchitis 7 (16) 10 (15) NS
Surgical site infection 9 (21) 8 (12) NS
Urinary tract infection 5 (12) 12 (18) NS
Skin and soft tissue infection 2 (5) 7 (11) NS
Phlebitis 2 (5) 3 (5) NS
Meningitis 1 (2) 3 (5) NS
Primary bacteraemia 2 (5) 1 (2) NS
Mortality 12 (28) 17 (26) NS
IMP-R Ab, imipenem-resistant Acinetobacter baumannii; IMP-S Ab, imipenem-
susceptible Acinetobacter baumannii; NS, not significant.
Table 3. Univariate analysis of risk-factors for nosocomial
acquisition of imipenem-resistant Acinetobacter baumannii
Characteristica IMP-R Ab IMP-S Ab OR (95% CI) p
Mean age, years 54.7 54.0 1.00 (0.9–1.0) 0.8
Chronic underlying
disease
61 (69) 85 (74) 0.88 (0.44–1.77) 0.4
Male gender 62 (70) 84 (73) 0.88 (0.45–1.71) 0.6
Hospital size > 500 beds 85 (97) 90 (78) 7.87 (2.15–34.0) < 0.001
Previous hospital stay,
days
22.3 28.1 0.98 (0.97–1.00) 0.1
Previous ICU stay 72 (82) 69 (60) 3.00 (1.43–6.12) 0.001
ICU ward 56 (64) 47 (41) 2.53 (1.37–4.68) 0.001
Intravenous catheter 74 (84) 64 (56) 4.21 (2.04–8.82) < 0.001
Intra-arterial catheter 39 (44) 30 (26) 2.26 (1.20–4.26) 0.007
Urinary catheter 80 (91) 81 (70) 4.20 (1.73–10.5) < 0.001
Nasogastric tube 44 (50) 34 (30) 2.38 (1.22–4.43) 0.003
Parenteral nutrition 27 (31) 25 (22) 1.59 (0.81–3.15) 0.1
Mechanical ventilation 61 (69) 52 (45) 2.74 (1.47–5.12) 0.001
Antimicrobial treatment 82 (93) 80 (70) 5.98 (2.25–16.8) < 0.001
Mean number of
antimicrobial agents
2.3 1.5 1.61 (1.28–2.02) < 0.001
Carbapenems 20 (23) 14 (12) 2.12 (0.95–4.79) 0.04
Aminopenicillins 23 (26) 22 (19) 1.50 (0.73–3.06) 0.2
Piperacillin–tazobactam 15 (17) 12 (10) 1.76 (0.73–4.30) 0.1
Cephalosporins 40 (45) 30 (26) 2.36 (1.25–4.46) 0.004
Aminoglycosides 35 (40) 28 (24) 2.05 (1.08–3.92) 0.01
Fluoroquinolones 16 (18) 18 (16) 1.20 (0.54–2.67) 0.6
Surgical treatment 56 (64) 40 (35) 3.28 (1.77–6.12) < 0.001
aUnless otherwise indicated, data are the number (%) of patients with each
characteristic.
IMI-R Ab, imipenem-resistant Acinetobacter baumannii; IMI-S Ab, imipenem-sus-
ceptible A. baumannii; ICU, intensive care unit.
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genotypes, and 14 of the 15 participating centres
yielded isolates belonging to a single clone [9]. It
has been suggested that antimicrobial resistance
is the main risk-factor allowing epidemic spread
of A. baumannii [29], but it may be the local
circumstances of each centre that influence the
occurrence of outbreaks involving monoclonal
dissemination, followed by the development of
endemic polyclonal IMP-R A. baumannii infec-
tions ⁄ colonisations.
Hospital size has not been described previously
as a risk-factor, but this probably reflects the
greater complexity of care needed by patients
admitted to large hospitals, and therefore the
higher numbers of patients at risk and healthcare
staff. The consumption of antimicrobial agents is
greater and the density of susceptible patients is
higher than in small hospitals. Finally, once an
epidemic has begun, it is more difficult to control.
This risk-factor can be influenced by improving
and intensifying the measures for prevention and
control of infection in large hospitals. Antimicro-
bial treatment is a risk-factor that has been
identified previously, with particular reference
to use of third-generation cephalosporins, imipe-
nem, aztreonam and quinolones [4,13,30,31]. Pre-
vious surgery and the presence of a urinary
catheter are risk-factors that reflect the high
workload in a high-risk unit (surgical ICU) [7].
There is a need to distinguish between colonisa-
tion and infection (which accounted for 47% of
the isolates in the present study), in order to avoid
unnecessary use of antimicrobial agents.
The present study was not without limitations.
The study design, comparing patients with IMP-R
and IMP-S A. baumannii, could overestimate the
influence of previous treatment with antimicrobial
agents. The level of environmental contamination,
a known risk-factor for outbreaks of A.baumannii
[32], was not analysed. Finally, as the study
covered a period of 1 month, there could be
seasonal variations in the incidence of infec-
tion ⁄ colonisation caused by A. baumannii. Never-
theless, the results suggest that IMP-RA. baumannii
is a widely distributed nosocomial pathogen in
Spain, and reaches an alarming prevalence in some
centres. Acquisition of IMP-R A. baumannii is
related strongly to hospital size, and may be
favoured by previous surgery, the presence of a
urinary catheter, and the selection pressure of
treatment with an antimicrobial agent. The
increase in the prevalence of this multiresistant
pathogen in Spain should lead to an immediate
response at the local and national levels to limit the
inappropriate use of antimicrobial agents, to
improve the diagnostic capacity for distinguishing
between colonisation and infection, and to rein-
force adherence to infection safeguard and control
measures.
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